Keywords: genentech, vegf, safe, efficacy, data, inconclusive, recombinant

Genentech's VEGF safe, but efficacy data are inconclusive

Article | 14 November 2000

Genentech's recombinant vascular endothelial growth factor has failed toproduce convincing results in a one-year follow-up of the VIVA trial, according ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Go to company listing

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing